MARCEL FILART: Open Payments
NPI 1396775474 · LOS ANGELES, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$882 in 32 payments from 9 companies in 2025. Trend: 2023 $389 · 2024 $331 · 2025 $882
Food & beverage: $790Education: $91
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 17 | $415 |
| Amgen Inc. | 7 | $190 |
| Lilly USA, LLC | 2 | $155 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| Alkermes, Inc. | 1 | $23 |
| Abbott Laboratories | 1 | $23 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $20 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $17 |
| Gilead Sciences, Inc. | 1 | $15 |
Products named: UZEDY, KRYSTEXXA, ZEPBOUND, AUSTEDO XR, MOUNJARO, OTEZLA, REXULTI, ARISTADA.
Industry payments across CA — which companies pay providers there.
